Actively Recruiting
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Led by Medical College of Wisconsin · Updated on 2026-01-26
200
Participants Needed
1
Research Sites
1195 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).
CONDITIONS
Official Title
PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants born at or after 34 weeks gestational age diagnosed with PPHN
- Healthy infants born at or after 34 weeks gestational age
You will not qualify if you...
- Diagnosed with lethal congenital anomalies
- Structural congenital heart disease except patent ductus arteriosus or patent foramen ovale
- Structural gastrointestinal tract abnormalities that could interfere with meconium passage
- Congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
G
G. Ganesh Konduri, MD
CONTACT
K
Kathleen M Meskin, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here